Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of sars-cov-2: a report of severe jaundice
Résumé
We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus.
This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group.
Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%).
Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.